Blocking MEK-ERK-RSK2 signaling results in reduced activation of several transcriptional regulators of proliferative genes in tumor cells (e.g. melanomas and myeloma) and suppresses cell growth [39]. The gene discussed is RPS6KA3; the disease is neoplasm.